AMPK/SNF1 structure: a menage a trois of energy-sensing

被引:17
作者
Scott, John W. [1 ]
Oakhill, Jonathan S.
van Denderen, Bryce J. W. [1 ,2 ]
机构
[1] Univ Melbourne, St Vincents Inst, Fitzroy, Vic 3065, Australia
[2] Univ Melbourne, Dept Med, Fitzroy, Vic 3065, Australia
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2009年 / 14卷
基金
英国医学研究理事会; 澳大利亚研究理事会;
关键词
AMP-activated protein kinase; AMPK; structure; metabolism; SNF1; Review; ACTIVATED-PROTEIN-KINASE; FATTY-ACID OXIDATION; PARKINSON-WHITE-SYNDROME; HMG-COA REDUCTASE; YEAST SNF1; SKELETAL-MUSCLE; GAMMA(2) SUBUNIT; CATALYTIC DOMAIN; BETA-SUBUNITS; 5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBONUCLEOSIDE;
D O I
10.2741/3266
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The AMP-activated protein kinase (AMPK) is the critical component of a highly conserved signalling pathway found in all eukaryotes that plays a key role in regulating metabolic processes in response to variations in energy supply and demand. AMPK protects cells from stresses that decrease cellular energy charge (i.e increase the AMP: ATP ratio) by initiating a shift in metabolism towards the generation of ATP while simultaneously down regulating pathways that consume ATP. The role of AMPK as an energy sensor extends beyond the cell and it is now apparent that it is a key regulator of whole-body energy homeostasis. These functions have stimulated considerable interest in AMPK as a promising target to treat metabolic disorders such as obesity and Type 2 diabetes. Recently, crystal structures of heterotrimeric core fragments and individual domains of AMPK from mammals, Schizosaccharomyces pombe and Saccharomyces cerevisiae have been solved. Together they provide an impressive insight into the molecular interactions involved in regulating kinase activity, heterotrimeric assembly, glycogen binding, and binding of the regulatory nucleotides AMP and ATP.
引用
收藏
页码:596 / 610
页数:15
相关论文
共 96 条
[1]  
AMODEO GA, 2007, NATURE
[2]   Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy [J].
Arad, M ;
Benson, DW ;
Perez-Atayde, AR ;
McKenna, WJ ;
Sparks, EA ;
Kanter, RJ ;
McGarry, K ;
Seidman, JG ;
Seidman, CE .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (03) :357-362
[3]   Effect of 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats [J].
Bergeron, R ;
Previs, SF ;
Cline, GW ;
Perret, P ;
Russell, RR ;
Young, LH ;
Shulman, GI .
DIABETES, 2001, 50 (05) :1076-1082
[4]   Mutations in the γ2 subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy:: evidence for the central role of energy compromise in disease pathogenesis [J].
Blair, E ;
Redwood, C ;
Ashrafian, H ;
Oliveira, M ;
Broxholme, J ;
Kerr, B ;
Salmon, A ;
Östman-Smith, I ;
Watkins, H .
HUMAN MOLECULAR GENETICS, 2001, 10 (11) :1215-1220
[5]   Kinase-independent transcriptional co-activation of peroxisome proliferator-activated receptor α by AMP-activated protein kinase [J].
Bronner, M ;
Hertz, R ;
Bar-Tana, J .
BIOCHEMICAL JOURNAL, 2004, 384 :295-305
[6]   Thiazolidinediones, like metformin, inhibit respiratory complex I -: A common mechanism contributing to their antidiabetic actions? [J].
Brunmair, B ;
Staniek, K ;
Gras, F ;
Scharf, N ;
Althaym, A ;
Clara, R ;
Roden, M ;
Gnaiger, E ;
Nohl, H ;
Waldhäusl, W ;
Fürnsinn, C .
DIABETES, 2004, 53 (04) :1052-1059
[7]   Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome [J].
Buhl, ES ;
Jessen, N ;
Pold, R ;
Ledet, T ;
Flyvbjerg, A ;
Pedersen, SB ;
Pedersen, O ;
Schmitz, O ;
Lund, S .
DIABETES, 2002, 51 (07) :2199-2206
[8]   Fatal congenital heart glycogenosis caused by a recurrent activating R531Q mutation in the γ2-subunit of AMP-activated protein kinase (PRKAG2), not by phosphorylase kinase deficiency [J].
Burwinkel, B ;
Scott, JW ;
Bührer, C ;
van Landeghem, FKH ;
Cox, GF ;
Wilson, CJ ;
Hardie, DG ;
Kilimann, MW .
AMERICAN JOURNAL OF HUMAN GENETICS, 2005, 76 (06) :1034-1049
[9]   Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase [J].
Carey, Andrew L. ;
Steinberg, Gregory R. ;
Macaulay, S. Lance ;
Thomas, Walter G. ;
Holmes, Anna G. ;
Ramm, Georg ;
Prelovsek, Oja ;
Hohnen-Behrens, Cordula ;
Watt, Matthew J. ;
James, David E. ;
Kemp, Bruce E. ;
Pedersen, Bente K. ;
Febbraio, Mark A. .
DIABETES, 2006, 55 (10) :2688-2697
[10]  
CARLING D, 1994, J BIOL CHEM, V269, P11442